Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18576605 | 1.00 | CYP1A2 (0.35) | CYP1A2ATML3MBTL1 | |
| SCHEMBL18576891 | 1.00 | CYP1A2 (0.35) | CYP1A2ATML3MBTL1 | |
| SCHEMBL16659519 | 0.94 | CYP1A2 (0.36) | CYP1A2ATML3MBTL1 | |
| SCHEMBL26050030 | 0.87 | KDM4E (0.32) | ATML3MBTL1 | |
| SCHEMBL8173461 | 0.87 | KDM4E (0.32) | ATML3MBTL1 | |
| SCHEMBL25102 | 0.87 | ATM (0.30) | ATML3MBTL1 | |
| SCHEMBL18899114 | 0.87 | ATM (0.30) | ATML3MBTL1 | |
| SCHEMBL8344135 | 0.87 | KDM4E (0.32) | ATML3MBTL1 | |
| SCHEMBL8166589 | 0.87 | KDM4E (0.32) | ATML3MBTL1 | |
| SCHEMBL24541 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170057993-A1 | Ether Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057950-A1 | Amide Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057993-A1 | Ether Compounds for Treatment of Medical Disorders | CFD, TFPI, F12 | CYP1A2 668/4885ATM 2410/4885L3MBTL1 3327/4885 |
| US-20170057950-A1 | Amide Compounds for Treatment of Medical Disorders | CFD, TFPI, CFH | CYP1A2 1689/4885ATM 1552/4885L3MBTL1 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.